3 of the Best ETFs to Buy and Hold if a Recession Is Coming

The article recommends three ETFs as defensive investments during an anticipated recession: Vanguard Healthcare ETF (VHT) for exposure to non-cyclical healthcare stocks, Vanguard Total Bond Market ETF (BND) to benefit from expected interest rate cuts, and Vanguard S&P 500 ETF (VOO) for long-term growth despite near-term volatility. Historical data shows the S&P 500 has delivered 10% annual returns despite recessions, suggesting buy-and-hold strategies outperform panic selling.

10/02/2026, 1:05 PM • The Motley Fool

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

09/30/2026, 4:54 AM • GlobeNewswire

Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

09/24/2026, 1:00 PM • GlobeNewswire

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

09/22/2026, 10:04 PM • The Motley Fool

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

09/21/2026, 1:00 PM • GlobeNewswire

The Investing Playbook for Retirees Who Can't Afford to Lose

The article provides a strategic framework for retirees on fixed incomes to protect their savings while managing inflation risk. It recommends a three-bucket approach: maintaining 12-24 months of expenses in cash/short-term fixed income, holding inflation-beating investments with dividend stocks, and allocating remaining funds to long-term growth stocks. The strategy emphasizes identifying essential expenses, calculating guaranteed income gaps, and using bond ladders and high-yield savings accounts to avoid forced asset sales during market downturns.

09/21/2026, 11:15 AM • The Motley Fool

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.

09/20/2026, 8:30 AM • The Motley Fool

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

The Stock Market Looks Shaky Right Now. History Says Dividend Growth Stocks Are Exactly What You Want to Own.

Amid current market volatility driven by high Treasury yields, elevated oil prices, and inflation concerns, dividend growth stocks offer a historically proven strategy for delivering higher returns with lower volatility. The iShares Core Dividend Growth ETF (DGRO) provides an easy way to invest in companies with at least five years of consecutive dividend growth, having delivered double-digit returns over multiple time periods with reduced volatility compared to the broader market.

09/16/2026, 10:08 AM • The Motley Fool

My Top 5 Favorite Stocks for an Uncertain Market

The article recommends five resilient stocks suitable for uncertain market conditions: Johnson & Johnson (pharmaceutical and medtech leader with 28 billion-dollar products), Vertex Pharmaceuticals (cystic fibrosis treatment market leader with pipeline expansion), Costco (essential goods retailer with high membership renewal rates), Coca-Cola (beverage company with strong brands and free cash flow), and American Express (payment card company with affluent customer base). These companies offer stability through essential products, strong market positions, and consistent dividend payments.

09/16/2026, 7:10 AM • The Motley Fool

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand

The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

09/16/2026, 4:55 AM • GlobeNewswire

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities

The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.

09/15/2026, 6:40 AM • GlobeNewswire

Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

Kenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol and Neutrogena. However, uncertainty exists due to a pending acquisition by Kimberly-Clark (KMB), another Dividend King with a 5.23% yield.

09/14/2026, 11:30 AM • The Motley Fool

State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors

XLV and IXJ are two healthcare ETFs with different approaches: XLV focuses on 60 U.S. S&P 500 healthcare stocks with a low 0.08% expense ratio and stronger recent returns, while IXJ offers broader global diversification with 110 holdings across multiple countries but charges a higher 0.38% expense ratio. The choice depends on whether investors prioritize cost efficiency and domestic concentration or international diversification.

09/13/2026, 5:24 PM • The Motley Fool

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

09/10/2026, 4:08 PM • The Motley Fool